Wikipedia

Probiotic Probio DR10

This is an old revision of this page, as edited by Zeebutt009 (talk | contribs) at 13:37, 23 January 2024 (removed unsourced content and fixed vandalism). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Overview

 
Bifidobacterium lactis HN019 under the microscope

Bifidobacterium animalis lactis HN019, commercially known as Probio DR10™, is a probiotic strain developed by the Fonterra Research Development Centre (FRDC).[1]

The origin of Probio DR10™ in the 1990s[1] marked a notable development in the field of probiotics. This era saw an increased focus on the role of probiotics in human health, especially regarding gut health and immune function. DR10™, isolated from yogurt—a common source of probiotics—demonstrates its natural adaptability to the human digestive system. The strain was initially isolated from yogurt, a traditional and common source of probiotics. The selection of DR10™ from yogurt not only signifies its natural occurrence but also underscores its inherent compatibility with the human gut environment. This origin is fundamental in the context of probiotics, as it suggests a natural symbiosis between the bacteria and the human digestive system.

A significant advancement in the understanding of DR10™ came with the publication of its complete genomic sequence in 2018.[2] This detailed genetic information has been essential in ensuring quality control, safety, and purity of the strain, which is critical in the probiotic industry where efficacy and safety are paramount. The adaptability of Probio DR10™ is evidenced by its incorporation into a range of products across the food and beverage, dietary supplement, and pharmaceutical industries.[3] This reflects the strain's stability and ability[3][4] to retain its beneficial properties in various product forms.

The distinction of Probio DR10™ lies in the scientific research and clinical trials that support its beneficial impact on gut health and immune support.[5]

Genomic Insights and Research

The scientific milestone in the journey of DR10™ was the publication of its complete genomic sequence in 2018.[2] This development was significant for several reasons:

Quality Control and Safety

The comprehensive genomic information of Bifidobacterium animalis lactis HN019, known as Probio DR10™, plays a crucial role in enhancing quality control and ensuring the safety of this probiotic strain. This aspect is particularly vital in the field of probiotics, where the efficacy and safety of the product are directly linked to the precise identity and purity of the strain used.

  1. Precise Strain Identification: The availability of complete genomic data allows for precise identification of the DR10™ strain. This is critical to ensure that the probiotic used in various products is indeed the specific strain that has been researched and shown to have health benefits. Accurate identification prevents the inadvertent substitution with other, potentially less effective or unsafe strains.
  2. Ensuring Genetic Consistency: The genetic blueprint of DR10™ serves as a reference for maintaining genetic consistency in every batch of the probiotic produced. This consistency is key to ensuring that the probiotic effects remain stable over time and across different product batches.
  3. Monitoring for Genetic Drift or Mutation: Over time, microorganisms can undergo genetic changes or mutations. Regular monitoring of the DR10™ strain against its original genomic sequence helps in detecting any such changes. This is important for maintaining the integrity and efficacy of the probiotic strain.
  4. Safety Assurance: The genomic sequence of DR10™ allows researchers and manufacturers to screen for the presence of any harmful genes, such as those that might confer antibiotic resistance or pathogenicity. This step is essential for ensuring that the strain is safe for consumption and does not pose any health risks to consumers.
  5. Contamination Control: With a clear genetic profile, it becomes easier to test for and control contamination. This includes avoiding cross-contamination with other bacterial strains during production and ensuring that the final probiotic product is free from unwanted microbial contaminants.
  6. Regulatory Compliance: Detailed genetic information supports compliance with regulatory requirements. Many health authorities require comprehensive data on probiotic strains to ensure their safety and efficacy. Having this information readily available facilitates the process of getting regulatory approvals for DR10™-containing products.

Benefits of Probio DR10™

Studies on the strain indicate positive effects on various aspects of the digestive system.[3] These include:

Immune system support

Probio DR10™ demonstrated extensive immune-stimulating effects in animal models as well as healthy adult and elderly clinical studies. In a randomised controlled trial (RCT) conducted with children aged 1 to 3 years, it was found that the incidence of high fever and severe acute lower respiratory infections was reduced by 5% and 35% respectively, in children who received the strain along with a prebiotic, in comparison to those who were administered a placebo.[6]

Modulation of intestinal microbiota

Probio DR10™ may increase the population of beneficial gut microflora of Bifidobacterium and Lactobacillus.[7][8][3]

The strain has also been shown to help maintain a healthy/normal gut microbiota against the ageing process by competing with and excluding harmful pathogens, operating at both taxonomical and functional levels.[3]

Maintenance of intestinal barrier functions

Probio DR10™ helps maintain the integrity of the gut epithelium, which is a layer of cells lining the inner surface of the intestine.[3] It also helps regulate the host immune defence against pathogens.[3]

A 2010 study also found that combining the strain with an oligosaccharide prebiotics results in a decrease in the incidence of dysentery.[6]

Regulation of gut motility and improvement of gastrointestinal symptoms

Probio DR10™ has demonstrated a positive effect on individuals suffering from constipation.[3] A New Zealand study involving 100 adults with functional gastrointestinal symptoms showed that the supplementation of the strain for 2 weeks alleviated constipation by reducing the gut transit time.[9]

Reductions in the frequency of other functional gastrointestinal symptoms, including vomiting, regurgitation, abdominal pain, nausea, gurgling, irregular bowel movements, diarrhoea and flatulence were also observed in the same study.[9]

Probio DR10™ may potentially divert colon fermentation towards the production of non-gaseous end products.[3] This characteristic of the strain may support tolerance for the fermentation of oligosaccharides within the body, which aligns with clinical findings that it reduces the occurrence of flatulence.[3]

Support for digestion

The fermentation of Probio DR10™ produces lactate and short-chain fatty acids (SCFAs) such as acetate, indicating their potential involvement in the digestion of dietary elements, without distinguishing between their source, whether it be carbohydrates or proteins.[3]

Mechanism of action

Probio DR10™ demonstrates an excellent ability to adhere to epithelial cells, a strong capacity to endure and survive in a low pH environment, resistance to bile salts as well as the ability to modulate the immune response.[4]

Studies indicate that this strain acts on intercellular junctions, especially tight junctions.[4] Tight junctions are situated in the most apical part of the cell and consist of two key proteins, claudin and occludin.[4] These proteins play a crucial role in establishing the epithelial barrier, which acts as a safeguard against the entry of macromolecules, including lipids and proteins.[4]

These junctions are vital for controlling the permeability of the epithelium.[4] Any changes in their function can lead to increased inflammation, and subsequently, the development of diseases.[4][10]

Safety

The presence of Bifidobacterium animalis subsp. lactis in human food has been documented since 1980, but it was likely part of human diets before that.[3]

The China National Center for Food Safety Risk Assessment (CFSA) has also approved the use of B. lactis in food for the general and paediatric population.[11]

A 2018 study found that the strain is well-tolerated in adults and did not induce changes in physical activity, food intake, or body weight.[12] It also has an established safety data in pregnant and lactating women as shown in studies.[13][14]

References

  1. ^ a b Gopal, Pramod; Dekker, James; Prasad, Jaya; Pillidge, Christopher; Delabre, Marie-Laure; Collett, Michael (2005). "Development and commercialisation of Fonterra's probiotic strains". Australian Journal of Dairy Technology. 60 (2): 173–182. INIST 17047956 ProQuest 199361400.
  2. ^ a b Ibarra, Alvin; Latreille-Barbier, Mathilde; Donazzolo, Yves; Pelletier, Xavier; Ouwehand, Arthur C. (2018-05-04). "Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial". Gut Microbes. 9 (3): 236–251. doi:10.1080/19490976.2017.1412908. ISSN 1949-0976. PMC 6219592. PMID 29227175.
  3. ^ a b c d e f g h i j k l Cheng, Jing; Laitila, Arja; Ouwehand, Arthur C. (14 December 2021). "Bifidobacterium animalis subsp. lactis HN019 Effects on Gut Health: A Review". Frontiers in Nutrition. 8. doi:10.3389/fnut.2021.790561. PMC 8712437. PMID 34970580.
  4. ^ a b c d e f g Araujo, Lisa Danielly Curcino; Furlaneto, Flávia Aparecida Chaves; da Silva, Léa Assed Bezerra; Kapila, Yvonne L. (19 August 2022). "Use of the Probiotic Bifidobacterium animalis subsp. lactis HN019 in Oral Diseases". International Journal of Molecular Sciences. 23 (16): 9334. doi:10.3390/ijms23169334. PMC 9409207. PMID 36012597.
  5. ^ Cheng, Jing; Laitila, Arja; Ouwehand, Arthur C. (2021-12-14). "Bifidobacterium animalis subsp. lactis HN019 Effects on Gut Health: A Review". Frontiers in Nutrition. 8. doi:10.3389/fnut.2021.790561. ISSN 2296-861X. PMC 8712437. PMID 34970580.
  6. ^ a b Sazawal, Sunil; Dhingra, Usha; Hiremath, Girish; Sarkar, Archana; Dhingra, Pratibha; Dutta, Arup; Verma, Priti; Menon, Venugopal P.; Black, Robert E. (13 August 2010). "Prebiotic and Probiotic Fortified Milk in Prevention of Morbidities among Children: Community-Based, Randomized, Double-Blind, Controlled Trial". PLOS ONE. 5 (8): e12164. Bibcode:2010PLoSO...512164S. doi:10.1371/journal.pone.0012164. PMC 2921405. PMID 20730056.
  7. ^ Gopal, Pramod K; Prasad, Jaya; Gill, Harsharnjit S (October 2003). "Effects of the consumption of Bifidobacterium lactis HN019 (DR10TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects". Nutrition Research. 23 (10): 1313–1328. doi:10.1016/S0271-5317(03)00134-9.
  8. ^ Ahmed, M.; Prasad, J.; Gill, H.; Stevenson, L.; Gopal, P. (2007). "Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects". The Journal of Nutrition, Health & Aging. 11 (1): 26–31. PMID 17315077. INIST 18554996 ProQuest 222242470.
  9. ^ a b Waller, Philip A; Gopal, Pramod K.; Leyer, Gregory J; Ouwehand, Arthur C.; Reifer, Cheryl; Stewart, Morgan E.; Miller, Larry E. (September 2011). "Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults". Scandinavian Journal of Gastroenterology. 46 (9): 1057–1064. doi:10.3109/00365521.2011.584895. PMC 3171707. PMID 21663486.
  10. ^ Turck, Dominique; Castenmiller, Jacqueline; De Henauw, Stefaan; Hirsch-Ernst, Karen Ildico; Kearney, John; Knutsen, Helle Katrine; Maciuk, Alexandre; Mangelsdorf, Inge; McArdle, Harry J; Naska, Androniki; Pelaez, Carmen; Pentieva, Kristina; Thies, Frank; Tsabouri, Sophia; Vinceti, Marco; s Bresson, Jean-Loui; Siani, Alfonso (July 2020). "Bifidobacterium animalis subsp. lactis Bi-07 contributes to increasing lactose digestion: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006". EFSA Journal. 18 (7): e06198. doi:10.2903/j.efsa.2020.6198. PMC 7388145. PMID 32742434.
  11. ^ "China National Center for Food Safety Risk Assessment" (PDF).
  12. ^ Ibarra, Alvin; Latreille-Barbier, Mathilde; Donazzolo, Yves; Pelletier, Xavier; Ouwehand, Arthur C. (4 May 2018). "Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial". Gut Microbes. 9 (3): 236–251. doi:10.1080/19490976.2017.1412908. PMC 6219592. PMID 29227175.
  13. ^ Noroyono Wibowo; Saptawati Bardosono; Rima Irwinda (31 December 2016). "Effects of Bifidobacterium animalis lactis HN019 (DR10^(TM)), inulin, and micronutrient fortified milk on faecal DR10^(TM), immune markers, and maternal micronutrients among Indonesian pregnant women". Asia Pacific Journal of Clinical Nutrition. 25 (S1): S102 – S110. doi:10.6133/apjcn.122016.s2. PMID 28027638.
  14. ^ Prescott, S. L.; Wickens, K.; Westcott, L.; Jung, W.; Currie, H.; Black, P. N.; Stanley, T. V.; Mitchell, E. A.; Fitzharris, P.; Siebers, R.; Wu, L.; Crane, J. (October 2008). "Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-γ and breast milk transforming growth factor-β and immunoglobin A detection". Clinical & Experimental Allergy. 38 (10): 1606–1614. doi:10.1111/j.1365-2222.2008.03061.x. PMID 18631345. S2CID 9492069.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Probiotic_Probio_DR10&oldid=1198221999"